Evgen Pharma PLC (AIM:EVG), CEO Dr Huw Jones and Chief Medical Officer, Dr Glen Clack present at the Proactive One2One Investor Forum – March 23rd 2023.
Evgen Pharma PLC is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases
The company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
Evgen Pharma’s lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has completed, with a positive outcome, a Phase 2a clinical trial for oestrogen-positive (ER+) metastatic breast cancer.
#ProactiveInvestors #EvgenPharma #ftse #FTSEAIM #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
source